Mirae Asset Global Investments’s GoodRx Holdings GDRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-26,300
Closed -$180K 1625
2024
Q3
$180K Sell
26,300
-7,100
-21% -$55.7K ﹤0.01% 1101
2024
Q2
$257K Sell
33,400
-148,112
-82% -$1.1M ﹤0.01% 1015
2024
Q1
$1.1M Buy
181,512
+68,835
+61% +$455K ﹤0.01% 1481
2023
Q4
$755K Sell
112,677
-32,293
-22% -$182K ﹤0.01% 1760
2023
Q3
$816K Sell
144,970
-11,272
-7% -$75.1K ﹤0.01% 1628
2023
Q2
$862K Sell
156,242
-7,168
-4% -$38.6K ﹤0.01% 1650
2023
Q1
$1.02M Sell
163,410
-3,572
-2% -$19.9K ﹤0.01% 1536
2022
Q4
$778K Sell
166,982
-58,517
-26% -$288K ﹤0.01% 1644
2022
Q3
$1.05M Sell
225,499
-11,997
-5% -$75.6K ﹤0.01% 1455
2022
Q2
$1.41M Buy
237,496
+30,579
+15% +$340K ﹤0.01% 1251
2022
Q1
$4M Sell
206,917
-31,309
-13% -$718K 0.01% 948
2021
Q4
$7.79M Sell
238,226
-76,565
-24% -$3.08M 0.02% 754
2021
Q3
$12.9M Sell
314,791
-61,175
-16% -$2.22M 0.03% 547
2021
Q2
$13.5M Buy
+375,966
New +$13.9M 0.04% 520

Other funds holding GDRX

Mirae Asset Global Investments's GDRX Position: Q4 2024 in Review

Mirae Asset Global Investments sold out of GoodRx Holdings (GDRX) in Q4 2024, closing a stake of 26,300 shares — an estimated $180K sold.

Mirae Asset Global Investments first reported a position in GDRX in Q2 2021 and held it in 14 quarters. The position peaked at $13.5M in Q2 2021. 170 funds tracked by Wall St. Rank hold GDRX as of Q4 2024.

  • Mirae Asset Global Investments reported no remaining GoodRx Holdings position as of Q4 2024 after selling out during the quarter.
  • Mirae Asset Global Investments sold 26,300 GoodRx Holdings shares in Q4 2024, an estimated $180K.
  • Mirae Asset Global Investments first reported a position in GoodRx Holdings in Q2 2021 and held it in 14 quarters.
  • Mirae Asset Global Investments's GoodRx Holdings position peaked at $13.5M in Q2 2021.
  • 170 funds tracked by Wall St. Rank held GoodRx Holdings as of Q4 2024.

Based on Mirae Asset Global Investments's 13F filing for Q4 2024, filed 27 Jan 2025.